With positive news like the above and further proof that CHK1 is effective in many cancer's in a combination should make this early deal for big pharma a no-brainer. The question is, will they wait until the safety profile is completed - more than likely yes. So it looks like it's going to be a dull summer, and i'm not talking about the weather. Tim could still pull something off yet though, like confirmation of funding from grant for chk1 - which would lift the share price, slightly. 2016 will be the year for Sareum IMO.
Hi cobalt. 'not a lot' I guess. However from one whose feeling a bit depressed with the entire aim biotechnology business, it's comforting to know someone's releasing some good news. Thanks for keeping us all on the straight and narrow. Best wishes. Freddie
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.